Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Concord Medical Starts $150 Million Healthcare Fund with Partner

publication date: Jan 13, 2017
Concord Medical Services, a Beijing company that operates a large China network of radiotherapy and diagnostic imaging centers, formed a $150 million healthcare investment fund with Zhongrong International Trust. Concord already runs 123 centers in hospitals across China; it says the capital will extend its reach and solidify its position in the sector. Concord has shown interest in owning hospitals over the last few years, which may also be a goal for the fund. The funds were evidently provided by Zhongrong; Concord has a market cap of just $200 million. More details....

Stock Symbol: (NYSE: CCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital